Tom Wikberg

651 total citations
17 papers, 572 citations indexed

About

Tom Wikberg is a scholar working on Pharmacology, Pharmacology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Tom Wikberg has authored 17 papers receiving a total of 572 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 5 papers in Pharmacology and 5 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Tom Wikberg's work include Diet and metabolism studies (4 papers), Pharmacology and Obesity Treatment (3 papers) and Drug-Induced Hepatotoxicity and Protection (3 papers). Tom Wikberg is often cited by papers focused on Diet and metabolism studies (4 papers), Pharmacology and Obesity Treatment (3 papers) and Drug-Induced Hepatotoxicity and Protection (3 papers). Tom Wikberg collaborates with scholars based in Finland. Tom Wikberg's co-authors include MariAnne Karlsson, J. Taskinen, A. Gordin, Pekka Ottoila, H. Rita, Annamari Vuorela, P J Pentikäinen, P. J. Pentik�inen, Tapani Keränen and Seppo Kaakkola and has published in prestigious journals such as Journal of Chromatography A, Drug Metabolism and Disposition and Journal of Pharmaceutical and Biomedical Analysis.

In The Last Decade

Tom Wikberg

17 papers receiving 540 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tom Wikberg Finland 12 264 110 84 76 75 17 572
Leonor Rivera‐Calimlim United States 15 379 1.4× 195 1.8× 164 2.0× 69 0.9× 101 1.3× 37 877
J. Taskinen Finland 14 86 0.3× 51 0.5× 67 0.8× 126 1.7× 214 2.9× 28 816
Usha Mishra United States 12 151 0.6× 79 0.7× 81 1.0× 15 0.2× 156 2.1× 29 669
Mukta Dooley 11 72 0.3× 133 1.2× 75 0.9× 24 0.3× 63 0.8× 17 655
G Sędek Switzerland 15 203 0.8× 184 1.7× 66 0.8× 33 0.4× 51 0.7× 26 659
T. Aaes‐Jørgensen Denmark 13 117 0.4× 270 2.5× 123 1.5× 200 2.6× 95 1.3× 24 820
Louis L. Radulovic United States 16 61 0.2× 224 2.0× 171 2.0× 74 1.0× 299 4.0× 25 973
Milena Rizzo Italy 16 162 0.6× 41 0.4× 173 2.1× 23 0.3× 196 2.6× 32 684
P. T. Mearrick Australia 9 133 0.5× 48 0.4× 42 0.5× 35 0.5× 43 0.6× 9 353
J. M. Gubbens‐Stibbe Netherlands 12 59 0.2× 25 0.2× 120 1.4× 64 0.8× 125 1.7× 16 483

Countries citing papers authored by Tom Wikberg

Since Specialization
Citations

This map shows the geographic impact of Tom Wikberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Wikberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Wikberg more than expected).

Fields of papers citing papers by Tom Wikberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Wikberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Wikberg. The network helps show where Tom Wikberg may publish in the future.

Co-authorship network of co-authors of Tom Wikberg

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Wikberg. A scholar is included among the top collaborators of Tom Wikberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Wikberg. Tom Wikberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Lehtonen, Päivi, et al.. (1999). Separation of the glucuronides of entacapone and its (Z)-isomer in urine by micellar electrokinetic capillary chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 721(1). 127–134. 10 indexed citations
2.
Lehtonen, Päivi, et al.. (1999). Micellar electrokinetic capillary chromatography method for direct determination of glucuronides of entacapone and its (Z)-isomer in human urine. Journal of Chromatography A. 836(1). 173–188. 11 indexed citations
3.
Karlsson, MariAnne, et al.. (1997). Automated Analysis of Levosimendan in Human Plasma by On-Line Dialysis and Liquid Chromatography. Biomedical Chromatography. 11(1). 54–58. 19 indexed citations
4.
Wikberg, Tom, et al.. (1996). Enantiomeric bioanalysis of simendan and levosimendan by chiral high-performance liquid chromatography. Chirality. 8(7). 511–517. 10 indexed citations
5.
Gordin, A., Markku Koulu, Mika Scheinin, et al.. (1996). COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers. Journal of Neural Transmission. 103(6). 729–736. 7 indexed citations
6.
Kaakkola, Seppo, A. Gordin, Sirpa Heinävaara, et al.. (1995). Effect of Entacapone, a COMP Inhibitor, on the Pharmacokinetics and Metabolism of Levodopa After Administration of Controlled-Release Levodopa-Carbidopa in Volunteers. Clinical Neuropharmacology. 18(1). 46–57. 46 indexed citations
7.
Wikberg, Tom & Annamari Vuorela. (1994). Metabolite profiles of two [14C]-labelled catechol O-methyltransferase inhibitors, nitecapone and entacapone, in rat and mouse urine and rat bile. European Journal of Drug Metabolism and Pharmacokinetics. 19(2). 125–135. 11 indexed citations
8.
Gordin, A., et al.. (1994). Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. European Journal of Clinical Pharmacology. 46(2). 151–7. 105 indexed citations
9.
Keränen, Tapani, A. Gordin, MariAnne Karlsson, et al.. (1993). The Effect of Catechol-O-Methyl Transferase Inhibition by Entacapone on the Pharmacokinetics and Metabolism of Levodopa in Healthy Volunteers. Clinical Neuropharmacology. 16(2). 145–156. 99 indexed citations
10.
Wikberg, Tom, Pekka Ottoila, & J. Taskinen. (1993). Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in the dog. European Journal of Drug Metabolism and Pharmacokinetics. 18(4). 359–367. 18 indexed citations
11.
Wikberg, Tom & J. Taskinen. (1993). Identification of major metabolites of the catechol-O-methyltransferase inhibitor nitecapone in the rat and dog.. Drug Metabolism and Disposition. 21(2). 325–333. 13 indexed citations
12.
Wikberg, Tom, Annamari Vuorela, Pekka Ottoila, & J. Taskinen. (1993). Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans.. Drug Metabolism and Disposition. 21(1). 81–92. 77 indexed citations
13.
Karlsson, MariAnne & Tom Wikberg. (1992). Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine. Journal of Pharmaceutical and Biomedical Analysis. 10(8). 593–600. 37 indexed citations
14.
Taskinen, J., et al.. (1991). Identification of major metabolites of the catechol-O-methyltransferase-inhibitor nitecapone in human urine.. Drug Metabolism and Disposition. 19(1). 178–183. 16 indexed citations
15.
Wikberg, Tom & J. Taskinen. (1991). Determination of a catechol-O-methyltransferase inhibitor, nitecapone, in human plasma and urine by liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis. 9(1). 59–64. 6 indexed citations
16.
Wikberg, Tom. (1991). Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis. 9(2). 167–176. 49 indexed citations
17.
Kaakkola, Seppo, A. Gordin, Mika Järvinen, et al.. (1990). Effect of a Novel Catechol-O-Methyltransferase Inhibitor, Nitecapone, on the Metabolism of l-Dopa in Healthy Volunteers. Clinical Neuropharmacology. 13(5). 436–447. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leonor Rivera‐Calimlim Breakdown of academic impact, for papers by J. Taskinen Breakdown of academic impact, for papers by Usha Mishra Breakdown of academic impact, for papers by Mukta Dooley Breakdown of academic impact, for papers by G Sędek Breakdown of academic impact, for papers by T. Aaes‐Jørgensen Breakdown of academic impact, for papers by Louis L. Radulovic Breakdown of academic impact, for papers by Milena Rizzo Breakdown of academic impact, for papers by P. T. Mearrick Breakdown of academic impact, for papers by J. M. Gubbens‐Stibbe
Rankless by CCL
2026